Back To: Home

CLICK HERE FOR WHAT'S NEW IN:
 




 

Roche, Galapagos end alliance
April 2013
SHARING OPTIONS:

MECHELEN, Belgium—Galapagos NV and Roche have announced the termination of a multi-indication alliance that has spanned more than three years. The companies first signed an alliance in December 2009 for chronic obstructive pulmonary disease, then broadened it to include fibrosis in December 2010. Following the termination, Roche will pay Galapagos €5.75 million, or approximately $7.48 million, for work completed in 2012, and Galapagos will retain worldwide rights to all fibrosis assays and the targets discovered during the alliance.
 
"We regret that Roche ended the alliance due to a strategic change, but the good news is that all assets have returned to Galapagos. Our plan is to find another partner to continue the search for compounds against these debilitating diseases," said Onno van de Stolpe, CEO of Galapagos.  
 

Back



PAGE UTILITIES


CONTACT US
DDNEWS
Published by Old River Publications LLC
19035 Old Detroit Road
Rocky River, OH USA 44116
Ph: 440-331-6600  |  Fax: 440-331-7563
 
© Copyright 2019 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.